Rosen Law Firm Urges BioVie Inc. Investors to Act Before Class Action Deadline

The Rosen Law Firm, recognized for its advocacy of investor rights globally, is issuing a reminder to investors who acquired BioVie Inc. BIVI securities during the period of August 5, 2021, to November 29, 2023. The firm is advising these individuals of the impending deadline on March 19, 2024, to apply to be a lead plaintiff in a securities class action lawsuit.

Understanding the Case

The lawsuit filed pertains to allegations that BioVie Inc. may have issued materially misleading business information to the investing public. Rosen Law Firm is positioned to ensure that affected investors of BIVI secure legal counsel to protect their rights and potentially recover their investments through the class action suit.

About BioVie Inc.

BioVie Inc., operating in the biotechnology sector, focuses on the innovation and advancement of drug treatments primarily within the United States. Headquartered in Santa Monica, California, their efforts are dedicated to confronting unmet medical needs through rigorous clinical research and development.

Action Steps for Affected Investors

Investors who purchased BIVI stock between the specified dates and incurred losses are encouraged to contact Rosen Law Firm to learn more about their options and rights. Joining the class action could possibly lead to compensation for financial damages. The deadline to apply as a lead plaintiff—a role that requires acting on behalf of other class members in directing the BIVI litigation—is set for March 19, 2024. Investors in BioVie Inc. are therefore urged not to delay in seeking legal advice and considering their involvement in the class action suit.

Rosen, BioVie, BIVI, ClassAction, Investors, Deadline